Compare GEOS & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | CYPH |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 73.3M |
| IPO Year | 1997 | 2019 |
| Metric | GEOS | CYPH |
|---|---|---|
| Price | $4.48 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.2K | ★ 14.4M |
| Earning Date | 11-19-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,803,000.00 | $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.48 | $0.49 |
| 52 Week High | $29.89 | $4.19 |
| Indicator | GEOS | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 31.79 | 46.25 |
| Support Level | N/A | $0.68 |
| Resistance Level | $5.40 | $3.23 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 14.93 | 10.58 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.